MJA
MJA

It’s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials

Med J Aust 2010; 192 (7): 393-396.
  • James W Denham1
  • Ron Bender2
  • William E J Paradice3

  • 1 Prostate Cancer Trials Group, University of Newcastle, Newcastle, NSW.
  • 2 New South Wales Police Force, Newcastle, NSW.
  • 3 Hunter Valley Research Foundation, Newcastle, NSW.


Competing interests:

None identified.

  • 1. MacKenzie R, Chapman S, Barrett A, Holding S. “The news is [not] all good”: misrepresentations and inaccuracies in Australian news media reports on prostate cancer screening. Med J Aust 2007; 187: 507-510. <MJA full text>
  • 2. Royal Australian College of General Practitioners. Prostate screening: policy endorsed by the 51st RACGP Council 6 May 2009. http://www.racgp.org.au/policy/Prostate_screening.pdf (accessed Dec 2009).
  • 3. Cancer Council Australia. Position statement: prostate cancer screening. http://www.cancer.org.au/File/PolicyPublications/Position_statements/PS-Prostate_cancer_screening_Apr08.pdf (accessed Dec 2009).
  • 4. Urological Society of Australia and New Zealand. USANZ PSA testing policy 2009. http://www.usanz.org.au/uploads/29168/ufiles/USANZ_2009_PSA_Testing_Policy_Final1.pdf (accessed Dec 2009).
  • 5. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
  • 6. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomised European study. N Engl J Med 2009; 360: 1320-1328.
  • 7. Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-591.
  • 8. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among US men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 636-644.
  • 9. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States. JAMA 2003; 289: 1414-1420.
  • 10. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316-381.
  • 11. Hammad FT. Radical prostatectomy. Ann N Y Acad Sci 2008; 1138: 267-277.
  • 12. Zhou EH, Ellis RJ, Cherullo E, et al. Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys 2009; 73: 15-23.
  • 13. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004; 71: 29-33.
  • 14. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
  • 15. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
  • 16. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290.
  • 17. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003; 21: 3972-3978.
  • 18. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850.
  • 19. Bouchardy C, Fioretta G, Rapiti E, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-429.
  • 20. Smith DP, Supramaniam R, Coates MS, Armstrong BK. Prostate cancer in New South Wales in 1972 to 1994. Sydney: NSW Cancer Council, 1998.
  • 21. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-184.
  • 22. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317: 307-312.
  • 23. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756.
  • 24. Coory MD, Baade PD. Urban–rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia. Med J Aust 2005; 182: 112-115. <MJA full text>
  • 25. Cancer Institute NSW. NSW Central Cancer Registry. Statistical reporting module. http://www.statistics.cancerinstitute.org.au (accessed Dec 2009).
  • 26. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-887.
  • 27. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 1420-1424.
  • 28. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101: 811-816.
  • 29. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106.
  • 30. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-1234.
  • 31. Klotz L. What is the best approach for screen-detected low volume cancers? — the case for observation. Urol Oncol 2008; 26: 495-499.
  • 32. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16-21.
  • 33. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 1297-1305.
  • 34. Baade PD, Steginga SK, Pinnock CB, Aitken JF. Communicating prostate cancer risk: what should we be telling our patients? Med J Aust 2005; 182: 472-475. <MJA full text>

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article